Skip to main content

Table 2 Haplogroup distribution of European non-Ashkenazi Jewish (Seph) T2DM patients who developed complications and the "No complications" group as in table 1. Patients included in this table may have more than one complication.

From: Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications

Haplogroup

All Seph n (%)

No complication n (%)

Cardiovascular n (%)

Retino-pathy n (%)

Nephro-pathy n (%)

U (nonK)

12 (6.5)

5 (7.7)

3 (5.4)

1 (2.7)

5 (7.7)

K

21 (11.3)

6 (9.2)

7 (12.5)

7 (18.9)

9 (13.8)

1HV*

17 (9.1)

4 (6.2)

5 (8.9)

7 (18.9)

10 (15.4)

H

49 (26.3)

17 (26.2)

16 (28.6)

6 (16.2)

14 (21.5)

J1**

16 (8.6)

5 (7.7)

3 (5.4)

4 (10.8)

8 (12.3)

T

26 (14)

12 (18.5)

7 (12.5)

4 (10.8)

4 (6.2)

N1b

7 (3.8)

2 (3.1)

2 (3.6)

2 (5.4)

3 (4.6)

WXI

12 (6.5)

4 (6.2)

3 (5.4)

3 (8.1)

3 (4.6)

2Others

26 (14)

10 (15.4)

10 (17.6)

3 (8.1)

9 (13.8)

Total

186

65

56

37

65

  1. 1HV* – see table 1. 2Others – see table 1. **After removing the J2 patients (see Materials and Methods), we were left only with J1 patients; thus, the sample size was reduced from 191 to 186 for the total population and the complications groups were adjusted accordingly.